Sign In
Buy CMMB
$1.72
-0.0200 (-1.15%)
At Close: Jun 03, 2026
—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Thursday, 15'th May 2025
— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M oderate/ A dvanced D isease R esulted in C ontinued I mprovements across K ey B iomarkers of Li ver
SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic a
Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
08:00am, Monday, 21'st Apr 2025
TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory disea
Chemomab Announces New Medical and Clinical Appointments
08:00am, Tuesday, 15'th Apr 2025
David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Ove
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
03:18pm, Thursday, 27'th Mar 2025
Chemomab Therapeutics Ltd. CMMB on Thursday released results from the Open Label Extension (OLE) portion of the Phase 2 Spring trial assessing nebokitug for primary sclerosing cholangitis (PSC).
Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis.
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis
08:00am, Thursday, 06'th Mar 2025
Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics,
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
08:00am, Monday, 03'rd Mar 2025
In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory approval
After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
07:00am, Tuesday, 03'rd Dec 2024
—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSW
Oral presentation at AASLD highlights broad clinical activity of Chemomab's CM-101 across multiple biomarkers and its disease-modifying potential in PSC
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
11:52am, Wednesday, 21'st Aug 2024
Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the second quarter of 2024. Chemomab Therapeutics reported earnings per share of -26 cents.
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Wednesday, 21'st Aug 2024
Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.
